Merck traded at 121.45 this Friday February 6th, decreasing 0.60 or 0.49 percent since the previous trading session. Looking back, over the last four weeks, Merck lost 4.63 percent. Over the last 12 months, its price fell by 13.34 percent. Looking ahead, we forecast Merck to be priced at 121.85 by the end of this quarter and at 111.38 in one year, according to Trading Economics global macro models projections and analysts expectations.
Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Performance Materials. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The Life Sciences business comprises the activities of MilliporeSigma, which provides solutions that facilitate biotechnology and pharmaceutical research. The product range includes laboratory water systems, gene editing tools, cell lines and end-to-end drug manufacturing systems, among others. The Performance Materials business provides specialty chemicals for various applications, including liquid crystals for electronic displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions.